Why the CSL share price was a market-beater in August

The CSL Limited (ASX:CSL) share price was a market-beater again in August. Is it too late to invest?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price continued its market-beating form in August with another solid gain.

The biotherapeutics giant's shares finished the period with a gain of 5.2%, stretching their year to date return to almost 40%.

Why did the CSL share price charge higher in August?

Investors were buying the company's shares last month after it reported another strong full year result.

In FY 2019 CSL posted revenue of US$8,539 million and a net profit after tax of US$1,919 million, which was an 11% and 17% constant currency increase, respectively, on FY 2018's results. The latter was at the upper end of its guidance range of US$1,880 million to US$1,950 million, exactly as management had promised.

Once again it was CSL's Immunoglobulins sales which were the key driver of its growth. Immunoglobulins sales increased 16% on the prior corresponding period to US$3,543 million in FY 2019.

Supporting this growth was a 6% lift in Speciality sales and a 15% jump in Albumin sales, leading to the CSL Behring business reporting an 11% increase in total revenue to US$7,343 million during the 12 months.

The company's Seqirus influenza vaccine business also performed strongly in FY 2019. The Seqirus business posted a 12% increase in total revenue to US$1,196 million. This solid result was driven by a 19% increase in the sales of seasonal influenza vaccines.

Also catching the eye of investors was management's guidance for the year ahead. Despite the one-off financial headwind of transitioning to a new model of direct distribution in China, management expects solid profit growth in FY 2020.

It has provided guidance for net profit after tax in the range of approximately $2,050 million to $2,110 million in constant currency, which represents annual growth of approximately 7% to 10%.

Is it too late to invest?

Although I think its shares are arguably fully valued now, if you're looking for long-term investments then I would still be a buyer of its shares today. This is due to the quality of the company and its solid long-term growth potential thanks to its current portfolio and potentially lucrative product pipeline.

In addition to CSL, I think Cochlear Limited (ASX: COH) and ResMed Inc. (ASX: RMD) would be outstanding buy and hold options in the healthcare sector.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors are sending these four ASX 200 stocks soaring this week. But why?

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why IGO, Johns Lyng, Lynas, and Web Travel shares are pushing higher today

These shares are ending the week on a high. But why?

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

Guess which 4 ASX 200 shares are rocking new 52-week highs today!

Investors just sent these four ASX 200 shares to one-year-plus highs.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Evolution Mining, Orthocell, Platinum, and Turaco shares are charging higher

These shares are having a better day that most on Thursday.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing hump day session for the ASX today.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to bank a small rise this Tuesday.

Read more »

Sport trainer talking to little girl who is climbing wooden ladder in gym.
Share Gainers

Why Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today

These shares are gaining on Tuesday, but why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Financial Shares

5 best ASX 200 financial shares of FY25 (CBA didn't make the cut!)

These stocks were well and truly 'in the black' for share price growth last financial year.

Read more »